The necessity for tumor markers which reflect tumor burden, patient response to therapy, and provide early indications of recurrent disease is an important and significant component for the present management of cancer patients. For gynecologic tumors no such markers existed. At this time, at least one promising tumor antigen CA125 has been documented and evaluated for use in serous ovarian cystadenocarcinomas. For ovarian cancer patients this finding has pertinence because of the latent nature of the disease in women in their post menopausal years. The proposal addresses the expression and characterization of CA125 in malignant ovarian carcinomas in benign disease and in normal tissues. Such information can impact a new understanding of continued or renewed expression of the gene in malignancy along with control of expression of the gene in normal tissue. It is proposed to study CA125 by utilizing a newly discovered source of the antigen in normal human tissues which previously was found only in trace amounts in mullerian duct derivatives. We have data which provides an insight into the subunit composition of the CA125 molecule and have developed polyclonal antibodies to the whole molecule. It is proposed to use this information and the polyclonal antibody reagent to evaluate the sub unit composition of the molecule from normal, benign and malignant tissues, to obtain sufficient amino acid sequence data for some of the subunits to be able to synthesize polynucleotide oligomers. These reagents will be used to probe a CDNA library made from chorion where a substantial concentration of CA125 antigen is located. The CDNA clones will be characterized for authenticity and used to screen and quantitate mRNA from normal and malignant tissues. In the future these probes will be further used to elucidate the structure and expression of the CA125 gene(s).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA040406-01A1
Application #
3180275
Study Section
Pathology B Study Section (PTHB)
Project Start
1986-04-01
Project End
1989-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
Schools of Medicine
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Fendrick, J L; Konishi, I; Geary, S M et al. (1997) CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol 18:278-89
de Groot, C J; O'Brien, T J; Taylor, R N (1996) Biochemical evidence of impaired trophoblastic invasion of decidual stroma in women destined to have preeclampsia. Am J Obstet Gynecol 175:24-9
Konishi, I; Fendrick, J L; Parmley, T H et al. (1994) Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line. J Soc Gynecol Investig 1:89-96
Fendrick, J L; Staley, K A; Gee, M K et al. (1993) Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line. Tumour Biol 14:310-8
Burks, A W; Williams, L W; Connaughton, C et al. (1992) Identification and characterization of a second major peanut allergen, Ara h II, with use of the sera of patients with atopic dermatitis and positive peanut challenge. J Allergy Clin Immunol 90:962-9
O'Brien, T J; Raymond, L M; Bannon, G A et al. (1991) New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Am J Obstet Gynecol 165:1857-64
Burks, A W; Williams, L W; Helm, R M et al. (1991) Identification of a major peanut allergen, Ara h I, in patients with atopic dermatitis and positive peanut challenges. J Allergy Clin Immunol 88:172-9
Hardardottir, H; Parmley 2nd, T H; Quirk Jr, J G et al. (1990) Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 163:1925-31
O'Brien, T J; Bannon, G A; Bard, D S et al. (1989) Expression of the ras oncogene in gynecologic tumors. Am J Obstet Gynecol 160:344-52
Long, C A; O'Brien, T J; Sanders, M M et al. (1988) ras oncogene is expressed in adenocarcinoma of the endometrium. Am J Obstet Gynecol 159:1512-6

Showing the most recent 10 out of 11 publications